Literature DB >> 21977060

Acute profound abciximab induced thrombocytopenia: a correct management of a methodological error.

Gaetano Tanzilli1, Martina Sordi, Alessio Arrivi, Enrico Mangieri, Massimiliano Scappaticci.   

Abstract

Thrombocytopenia is a rare complication of glycoprotein IIb/IIIa treatment. We report a case of an acute profound abciximab induced thrombocytopenia and its successful management. The patient, presenting with unstable angina, underwent percutaneous coronary intervention with implantation of three drug eluting stents without receiving a clopidogrel loading dose according to guidelines. The rapid drop in the platelet count after abciximab elastomeric pump infusion was treated with drug discontinuation and platelet transfusion. The high risk of stent thrombosis was avoided by a timely readministration of the dual antiplatelet treatment.

Entities:  

Year:  2009        PMID: 21977060      PMCID: PMC3030165          DOI: 10.1136/bcr.12.2008.1381

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

Review 1.  Heparin-induced thrombocytopenia: pathogenesis and management.

Authors:  Theodore E Warkentin
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

2.  Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy.

Authors:  L G Y Claeys; W Berg
Journal:  Eur J Vasc Endovasc Surg       Date:  2003-01       Impact factor: 7.069

Review 3.  Disposable infusion pumps.

Authors:  Elena A Skryabina; Teresa S Dunn
Journal:  Am J Health Syst Pharm       Date:  2006-07-01       Impact factor: 2.637

4.  Evaluation of the design and reliability of three elastomeric and one mechanical infusers.

Authors:  Monique Ackermann; Stéphanie Maier; Ho Ing; Pascal Bonnabry
Journal:  J Oncol Pharm Pract       Date:  2007-06       Impact factor: 1.809

5.  Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.

Authors:  D J Kereiakes; S D Berkowitz; A M Lincoff; J E Tcheng; K Wolski; R Achenbach; R Melsheimer; K Anderson; R M Califf; E J Topol
Journal:  Am Heart J       Date:  2000-07       Impact factor: 4.749

6.  Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.

Authors:  A M Lincoff; D B Mark; J E Tcheng; R M Califf; M V Bala; K M Anderson; L Davidson-Ray; J D Knight; C F Cabot; E J Topol
Journal:  Circulation       Date:  2000-12-12       Impact factor: 29.690

7.  Final results of the ReoPro readministration registry.

Authors:  Jean-Pierre Dery; Gregory A Braden; A Michael Lincoff; Dean J Kereiakes; Kevin Browne; Thomas Little; Barry S George; David C Sane; Douglas B Cines; Mark B Effron; Mary Ann Mascelli; Mary Ann Langrall; Lakshmi Damaraju; Elliot S Barnathan; James E Tcheng
Journal:  Am J Cardiol       Date:  2004-04-15       Impact factor: 2.778

Review 8.  Thrombocytopenia associated with the use of GPIIb/IIIa inhibitors: position paper of the ISTH working group on thrombocytopenia and GPIIb/IIIa inhibitors.

Authors:  R H Aster; B R Curtis; D W Bougie; S Dunkley; A Greinacher; T E Warkentin; B H Chong
Journal:  J Thromb Haemost       Date:  2006-03       Impact factor: 5.824

9.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.

Authors:  Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith; Alice K Jacobs; Cynthia D Adams; Jeffrey L Anderson; Elliott M Antman; Jonathan L Halperin; Sharon A Hunt; Harlan M Krumholz; Frederick G Kushner; Bruce W Lytle; Rick Nishimura; Joseph P Ornato; Richard L Page; Barbara Riegel
Journal:  J Am Coll Cardiol       Date:  2007-08-14       Impact factor: 24.094

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

View more
  1 in total

1.  Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.

Authors:  Todd Golden; Sehem Ghazala; Rita Wadeea; Shilpa Junna
Journal:  BMJ Case Rep       Date:  2017-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.